BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Company News  |  Deals

Excaliard, Pfizer deal

Pfizer acquired skin scarring therapy company Excaliard for an undisclosed upfront payment, plus milestones. Pfizer will gain EXC 001, an antisense oligonucleotide targeting connective tissue growth factor (CTGF) in Phase II testing...

Read the full 158 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >